FLT3 and myelodysplastic syndrome: Adults age ≥ 18 with secondary AML, MDS, CMML with elevated blasts or high risk features undergoing first allo-HSCT. Patients with sAML with FLT3-mutation, or marrow blasts ≥30% excluded.